• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MMP2 Gene Record

  • Summary
  • Interactions
  • Claims
  • MMP2 4313 Druggable Genome

    Alternate Names:

    4313
    MATRIX METALLOPEPTIDASE 2
    MMP2
    CLG4
    CLG4A
    MMP-2
    MMP-II
    MONA
    TBE-1
    120360
    7166
    ENSG00000087245
    OTTHUMG00000133202
    P08253
    72 KDA TYPE IV COLLAGENASE
    MATRIX METALLOPROTEINASE-2
    MMP2_HUMAN
    72 KDA TYPE IV COLLAGENASE PRECURSOR (EC 3.4.24.24) (72 KDA GELATINASE) (MATRIX METALLOPROTEINASE-2) (MMP-2) (GELATINASE A) (TBE- 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P08253]
    3549
    T68251

    Gene Info:

    Target Main Class Enzymes
    Target Subclass 3.4.24.24
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name Peptidase, metallopeptidase
    Interpro Type Domain
    Interpro Acc IPR006026
    Uniprot Status Swiss-Prot
    Human Readable Name DRUGGABLE GENOME
    Human Readable Name PROTEASE
    Interpro Short Name Peptidase_Metallo
    Target Class Enzymes
    Target Subclass EC:3.4.24.24
    Gene Biotype PROTEIN_CODING
    (11 More Sources)

    Gene Categories: Category Details

    NEUTRAL ZINC METALLOPEPTIDASE
    PROTEASE
    DRUGGABLE GENOME
    ENZYME

    Publications:

    Bernardo et al., 2002, Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases., J. Biol. Chem.
    Fanchon et al., 2004, Involvement of matrix metalloproteinases in the onset of dentin mineralization., Eur. J. Oral Sci.
    Bourd-Boittin et al., 2005, Matrix metalloproteinase inhibition impairs the processing, formation and mineralization of dental tissues during mouse molar development., Exp. Cell Res.
    Shinoda et al., 2003, A novel matrix metalloproteinase inhibitor, FYK-1388 suppresses tumor growth, metastasis and angiogenesis by human fibrosarcoma cell line., Int. J. Oncol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Treharne et al., 1999, Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease., Br J Surg
    Rizvi et al., 2004, A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer., Clin. Cancer Res.
    Huang et al., 2006, Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients., Eur. J. Clin. Invest.
    Zheng et al., 2005, [Effects of interaction between vascular endothelial cells and monocytes on expression of matrix metalloproteinase-2 and of tissue inhibitor of metalloproteinases 2 and regulation of pravastatin]., Zhonghua Bing Li Xue Za Zhi
    Wang et al., 1996, Cytokine regulation of the matrix metalloproteinases and their inhibitors in human papillomavirus-18 transformed human prostatic tumor cell lines., Oncol. Res.
    Vacca et al., 1999, Antiangiogenesis is produced by nontoxic doses of vinblastine., Blood
    Sugimoto et al., 2001, Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells., Int. J. Cancer
    Wu et al., 1997, Altered kidney matrix gene expression in early stages of experimental diabetes., Acta Anat (Basel)
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
    Gendron et al., 1999, Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine., Clin. Diagn. Lab. Immunol.
    Bolbrinker et al., 2006, Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension., J. Pharmacol. Exp. Ther.
    Bianchi et al., 2003, Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart., Int. Immunopharmacol.
    Clutter et al., 2006, Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells., Exp. Hematol.
    Gagliano et al., 2005, Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and Secreted Protein Acidic and Rich in Cysteine (SPARC) on human cultured glioblastoma cells., Biomed. Pharmacother.
    Mitropoulou et al., 2003, Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells., Int. J. Cancer
    Westerlund et al., 1997, Ovarian cancer cell invasion is inhibited by paclitaxel., Clin. Exp. Metastasis
    Lee SK et al., 2007, Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2., Bioorg Med Chem
    Tabouret et al., 2016, MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study., Oncotarget
    Lee YJ et al., 2012, Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice., Eur J Med Chem
  • OBOVATAL   MMP2

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17428670


    Sources:
    DTC

  • REBIMASTAT   MMP2

    Interaction Score: 5.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15041713


    Sources:
    NCI

  • MARIMASTAT   MMP2

    Interaction Score: 3.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Novel Target
    Trial Name -

    PMIDs:
    11790786 15056115 15748894 12527923 11752352 10460642


    Sources:
    TdgClinicalTrial TEND TTD

  • INCYCLINIDE   MMP2

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Novel Target
    Trial Name COL-3,Metastat

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TTD

  • S-3304   MMP2

    Interaction Score: 1.29

    Interaction Types & Directionality:
    vaccine (activating)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • RAMIPRIL   MMP2

    Interaction Score: 1.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16166267


    Sources:
    NCI

  • DEMETHYLWEDELOLACTONE   MMP2

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22926226


    Sources:
    DTC

  • PERFOSFAMIDE   MMP2

    Interaction Score: 0.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17046572


    Sources:
    NCI

  • PRINOMASTAT   MMP2

    Interaction Score: 0.74

    Interaction Types & Directionality:
    vaccine (activating)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC TTD

  • ZILEUTON   MMP2

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • FILGRASTIM   MMP2

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11391619


    Sources:
    NCI

  • ACETAZOLAMIDE   MMP2

    Interaction Score: 0.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • LETROZOLE   MMP2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12569569


    Sources:
    NCI

  • DEFEROXAMINE   MMP2

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • CHLORHEXIDINE   MMP2

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10225852


    Sources:
    NCI

  • ALDESLEUKIN   MMP2

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8938794


    Sources:
    NCI

  • VINBLASTINE   MMP2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10590059


    Sources:
    NCI

  • BEVACIZUMAB   MMP2

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26921265


    Sources:
    CIViC

  • PRAVASTATIN   MMP2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15842807


    Sources:
    NCI

  • RESVERATROL   MMP2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16084059


    Sources:
    NCI

  • STREPTOZOCIN   MMP2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9394952


    Sources:
    NCI

  • SIMVASTATIN   MMP2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16436088


    Sources:
    NCI

  • CYCLOSPORINE   MMP2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12639820


    Sources:
    NCI

  • PACLITAXEL   MMP2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9174131


    Sources:
    NCI

  • Ensembl: ENSG00000087245

    • Version: 101_38

    Alternate Names:
    MMP2 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • RussLampel: ENSG00000087245

    • Version: 26-July-2011

    Alternate Names:
    72 KDA TYPE IV COLLAGENASE PRECURSOR (EC 3.4.24.24) (72 KDA GELATINASE) (MATRIX METALLOPROTEINASE-2) (MMP-2) (GELATINASE A) (TBE- 1). [SOURCE:UNIPROT/SWISSPROT;ACC:P08253] Description
    MMP2 Display Id
    ENSG00000087245 Ensembl Gene Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P08253

    • Version: 01-August-2011

    Alternate Names:
    4313 Entrez Gene Id
    P08253 Uniprot Accession
    MMP2_HUMAN Uniprot Id

    Gene Info:
    Target Subclass 3.4.24.24
    Target Main Class Enzymes

    Publications:

  • HopkinsGroom: P08253

    • Version: 11-September-2012

    Alternate Names:
    MMP2_HUMAN Uniprot Id
    ENSG00000087245 Ensembl Gene Id
    72 KDA TYPE IV COLLAGENASE Uniprot Protein Name

    Gene Info:
    Uniprot Evidence 1: Evidence at protein level
    Interpro Name Peptidase, metallopeptidase
    Interpro Type Domain

    Gene Categories:
    PROTEASE, DRUGGABLE GENOME

    Publications:

  • TdgClinicalTrial: P08253

    • Version: January-2014

    Alternate Names:
    MMP2 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:3.4.24.24

    Publications:

  • CIViC: MMP2

    • Version: 14-September-2020

    Alternate Names:
    4313 Entrez Gene ID
    3549 CIViC Gene ID

    Gene Info:

    Publications:
    Tabouret et al., 2016, MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study., Oncotarget

  • NCI: MMP2

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Bianchi et al., 2003, Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart., Int. Immunopharmacol.
    Clutter et al., 2006, Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells., Exp. Hematol.
    Mitropoulou et al., 2003, Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells., Int. J. Cancer

  • DTC: MMP2

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
    Lee YJ et al., 2012, Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice., Eur J Med Chem
    Lee SK et al., 2007, Inhibitory effect of obovatal on the migration and invasion of HT1080 cells via the inhibition of MMP-2., Bioorg Med Chem

  • TALC: MMP-2

    • Version: 12-May-2016

    Alternate Names:
    MMP-2 Gene Symbol

    Gene Info:

    Publications:

  • HingoraniCasas: ENSG00000087245

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000087245 Gene Symbol
    MMP2 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TALC: MMP2

    • Version: 12-May-2016

    Alternate Names:
    MMP2 Gene Symbol

    Gene Info:

    Publications:

  • GO: MMP2

    • Version: 01-February-2022

    Alternate Names:
    CLG4A GO Gene Synonym

    Gene Info:

    Gene Categories:
    NEUTRAL ZINC METALLOPEPTIDASE

    Publications:

  • dGene: MMP2

    • Version: 27-Jun-2013

    Alternate Names:
    4313 Gene ID
    CLG4 dGene Synonym
    CLG4A dGene Synonym

    Gene Info:

    Gene Categories:
    PROTEASE

    Publications:

  • TTD: Matrix metalloproteinase-2

    • Version: 2020.06.01

    Alternate Names:
    MMP-2 TTD Gene Abbreviation
    T68251 TTD Target ID

    Gene Info:

    Publications:

  • Pharos: MMP2

    • Version: 01-February-2022

    Alternate Names:
    72 kDa type IV collagenase Gene Name
    P08253 UniProt ID

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21